DeRoyal

INDUSTRY OUTLOOK

BIOMEDICAN | December 03, 2020

BIOMEDICAN, a biotech organization planning patented minimal methods for developing high-value compounds at scale with proprietary yeasts, has entered the Astaxanthin market to diversify products outside of Cannabinoids. This new advancement permits BIOMEDICAN's biosynthesis platform to focus on any high-value compound and fundamentally disturb the current advances. Astaxanthin is a widely used, high-value compound known as a powerful antioxidant and anti-inflammatory. The Ast...

RESEARCH

Prellis Biologics, Inc. | January 14, 2022

Prellis Biologics, Inc. (Prellis), a Bay Area biotechnology company, announced that it has entered into a multi-target drug discovery collaboration and licensing agreement with Bristol Myers Squibb utilizing Prellis Biologics’ first-in-class externalized human immune system based on human lymph node organoids. The collaboration leverages Prellis’ EXIS platform that can break tolerance mechanisms in vitro to create high affinity human antibodies targeting human proteins. ...

CELL AND GENE THERAPY

Curi Bio Inc. | December 30, 2021

Curi Bio Inc., a leading developer of human stem cell-based platforms for drug discovery, announced the second closing of a $10 million oversubscribed Series A financing. New investors include UTC Investment and DS Asset Management, joining current Curi Bio investor and Series A lead Dynamk Capital. The investment will be used to scale Curi’s existing business and accelerate the development of its innovative engineered tissue analysis platforms, including its Mantarray™ platform.
Read More

CELL AND GENE THERAPY

Aktis Oncology | August 24, 2022

Aktis Oncology, a biotechnology company discovering and developing novel classes of targeted alpha radiopharmaceuticals to treat a broad range of solid tumors, today announced agreements with three leading medical radioisotope manufacturers NorthStar Medical Radioisotopes LLC, Niowave, Inc, and TerraPower LLC, for preclinical, clinical, and commercial supply of Actinium-225. "Given the breadth and depth of our emerging pipeline, securing robust isotope s...